High on-treatment platelet reactivity - why should we be concerned?

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 789-791

  Huber, Kurt ^a   Schrör, Karsten ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATOPAXAR; CLOPIDOGREL; CYCLOOXYGENASE 1; DIPYRONE; IBUPROFEN; PARACETAMOL; PRASUGREL; PROTON PUMP INHIBITOR; RIVAROXABAN; TICAGRELOR; VORAPAXAR;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; EDITORIAL; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877078909     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0281     Document Type: Editorial

References (40)

1. Silber S, Albertsson P, Aviles F, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847
2. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555
3. Cattaneo M. High on-treatment platelet reactivity - definition and measurement. Thromb Haemost 2013; 109: 792-798
4. Bernlochner I, Mayer K, Morath T, et al. Antiplatelet efficacy of prasugrel in patients with high onclopidogrel treatment platelet reactivity and a history of coronary stenting. Thromb Haemost 2013; 109: 517-524
5. Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727
6. Goto S, Tomiya A. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter? Thromb Haemost 2013; 109: 177-178
7. Jaitner J, Stegherr J, Morath T, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-112
8. Marcucci R, Gori AM, Paniccia R, et al. High ontreatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104: 279-286
9. Saucedo JF, Angiolillo DJ, DeRaad R, et al. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355
10. Brouwer MA, Jaspers Focks J, Verheugt FWA. High platelet reactivity - the challenge of prolonged anticoagulation therapy after ACS. Thromb Haemost 2013; 109: 799-807
11. Dahlen JR, Price MJ, Parise H, et al. Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thromb Haemost 2013; 109: 808-816
12. Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-824
13. Hohlfeld T, Saxena A, Schrör K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109: 825-833
14. Trenk D, Kristensen SD, Hochholzer W, et al. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. Thromb Haemost 2013; 109: 834-845
15. Cesari F, Marcucci R, Gori AM, et al. Reticulated platelets predict cardiovascular death in acute coronary syndrom patients. Insights from the AMIFlorence 2 Study. Thromb Haemost 2013; 109: 846-853
16. Siller-Matula J, Schror K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393
17. Höchtl T, Tentzeris I, Schrör K, et al. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundam Clin Pharmacol 2012; 26: 2-10
18. Yukhanyan L, Freynhofer MK, Siller-Matula J, et al. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost 2011; 105 Suppl 1: S55-59
19. Tentzeris I, Siller-Matula J, Farhan S, Jet al. Platelet function variability and non-genetic causes. Thromb Haemost 2011; 105 Suppl 1: S60-S66
20. Shuldiner AR, Bilden KP, Gandhi A, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857
21. Siller-Matula JM, Jilma B, Schror K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624-2641
22. Tentzeris I, Jarai R, Farhan S, et al. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost 2010; 104: 1211-1218
23. Freynhofer MK, Bruno V, Wojta J, et al. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18: 5197-5214
24. Wallentin L, Becker R, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057
25. Wiviott S, Trenk D, Frelinger A, et al. Prasugrel compared with high loading- and maintenancedose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932
26. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19
27. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thrombos Haemost 2011; 106: 572-584
28. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571
29. Lip G, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28
30. Dewilde W, Oirbasn T, Verheugt FW, et al. The WOEST Trial: First randomised trial comparing two regimens with and without apsirin in patients on oral anticoagulation therapy undergoing coronary stenting. ESC Annual Scientific Session; 2013 August 28; Munich, Germany.
31. Morrow DA, Braunwald E, Bonaca MP, et al. TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413
32. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33
33. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012; 380: 1317-1324
34. Paniccia R, Antonucci E, Maggini N, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010; 104: 287-292
35. Jeong YH, Bliden KP, Tantry US, et al. High ontreatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost 2012; 10: 487-489
36. Aradi D, Komócsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2012; Epub ahead of print.
37. Schrör K, Huber K, Hohlfeld T. Functional testing methods for the antiplatelet effects of aspirin. Biomark Med 2011; 5: 31-42
38. Valgimigli M, Tebaldi M, Campo G, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012; 5: 268-277
39. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-1864
40. Kovács EG, Katona E, Bereczky Z, et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res 2013; 131: 320-324.